

Exploring new frontiers in treating stroke



AND OTHER NEUROLOGICAL CONDITIONS

The global impact of stroke is staggering

Stroke is the
#1 cause of disability
and
#2 cause of death
worldwide.


The estimated
global cost of stroke is
\$721 billion.¹

Over
143 million years
of healthy lives are lost
each year to ischemic
stroke-related death
and disability.¹

Caregivers are also affected and can experience physical challenges in caring for their loved one, as well as depression, anxiety, social isolation and financial stress.²

Few people are eligible for current treatment options

An ischemic stroke occurs when blood flow to the brain is blocked. Without oxygen, brain cells begin to die within minutes.



Only **~20% of those with stroke are eligible to receive currently available treatment options**, including endovascular thrombectomy (clot removal) or thrombolytics (clot-busting drugs), leaving **~80% of people at risk** for brain damage and long-term disability.³

With RNS60, hope is on the horizon

Clinical-stage pharmaceutical company Revalerio is exploring new frontiers in treating stroke and other neurological disorders. According to an expert stroke neurologist, Revalerio is on the cusp of "redefining the treatment of stroke." A new investigational drug, RNS60, showed positive results in a placebo-controlled Phase 2 clinical trial when RNS60 was compared to placebo in stroke patients receiving endovascular thrombectomy.*

Revalerio is pioneering a novel technology platform that harnesses fluid physics to generate therapeutics that preserve brain tissue in settings of acute neuronal injury such as ischemic stroke and slow disease progression in chronic neurodegenerative diseases, thereby improving quality of life.

RNS60 demonstrated⁴



- **50% reduction** in loss of brain tissue
- Improvement in all prespecified **clinical outcomes**
- Large numerical **improvement in Modified Rankin Scale** (FDA primary endpoint)
- **Safely administered** and **well tolerated** among clinical trial participants


Revalerio is planning to replicate these results in a pivotal Phase 3 clinical trial in a larger number of participants, which could serve as the basis for FDA and EMA approval, potentially impacting millions of lives in the US and beyond.



The promise of RNS60 extends well beyond stroke, with the potential to address:

ALS
(promising clinical data)

Traumatic brain injury



Alzheimer's disease

Other debilitating neurological conditions

[Learn more at revalerio.com](https://revalerio.com)

EMA = European Medicines Agency; FDA = Food and Drug Administration.

*RNS60 is an investigational drug currently being evaluated in clinical trials and has not approved by a regulatory authority, such as the FDA.

References: 1. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. 2. Omar O, et al. *Cureus*. 2021;13(9):e17948. doi: 10.7759/cureus.17948.

3. Anand SK, et al. *J Neurosurg*. 2021;51(1):E2. doi:10.3171/2021.4.FOCUS21117. 4. Revalerio press release: <https://revalerio.com/press-releases/revalerio-announces-positive-topline-data-from-phase-2-rescue-study-of-rns60-in-patients-with-acute-ischemic-stroke-in-late-breaking-oral-presentation-at-isc-2024/>

©2025 Revalerio Corporation. All rights reserved.

